# A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC

Source: https://onco.cc/trials/nct07720193/  
OnCo record `nct07720193` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, not yet recruiting.

## Summary

A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC is a phase 3 interventional study registered as NCT07720193 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2026-11-16. Conditions recorded: Advanced Extrapulmonary Neuroendocrine Carcinoma. Interventions recorded: LBL-024 for Injection, Etoposide injection, Cisplatin injection, Carboplatin injection and LBL-024 placebo for injection.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07720193
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled, Phase III Trial of LBL-024 Combined With Platinum-based Chemotherapy as First-line Treatment of Patients With Advanced Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 280

## Sources

- ClinicalTrials.gov NCT07720193: https://clinicaltrials.gov/study/NCT07720193

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- drugs: [Opamtistomig](https://onco.cc/drugs/opamtistomig/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07720193.json